Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.

NCT02387606 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG: Placebo
DRUG: JNJ-53718678

Sponsor

Janssen Sciences Ireland UC